STRATEGY FOR CLONING AND EXPRESSING THE EXTRACELLULAR DOMAINS OF RECEPTORS AS SOLUBLE PROTEINS

• US 20100249022A1
• Filed: 05/15/2008
• Published: 09/30/2010
• Est. Priority Date: 05/18/2007
• Status: Abandoned Application

• Current Assignee: University Of Massachusetts
• Original Assignee: University Of Massachusetts
• Inventors: Repik, Alexander, Clapham, Paul
• Application Number:
  US12/600,785
• Publication Number:
  US 20100249022A1
• Time in Patent Office: Days
• US Class Current: 514/3.800
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748

Abstract

The present invention relates generally to soluble G protein-coupled receptor constructs. More specifically, the invention relates to soluble chemokine receptors, and soluble HIV co-receptors in particular. The invention is generally useful for designing and constructing soluble GPCR, which may be used to identify binding molecules. The invention also relates to methods of treating and/or preventing a disease or disorder associated with impaired function of such a receptor. The invention thus provides compositions and methods for therapeutic applications, such as vaccine.

Claims

1. A soluble polypeptide that retains three dimensional conformation of a native G protein-coupled receptor (GPCR) protein comprising:

at least two extracellular domains of a GPCR protein, linked in tandem by short inter-domain linkers to form a soluble polypeptide that retains three dimensional conformation of a native GPCR corresponding to the extracellular domains of the GPCR protein, wherein the soluble polypeptide is capable of binding a ligand or functionally equivalent analog thereof for the native GPCR protein.

2. The soluble polypeptide of claim 1, wherein the GPCR protein is CCR5.

3. The soluble polypeptide of claim 1, wherein the GPCR protein is CXCR4.

4. The soluble polypeptide of claim 1, further comprising a tag.

5. The soluble polypeptide of claim 4, wherein the tag is a His6 tag.

6. The soluble polypeptide of claim 4, wherein the polypeptide comprises a carboxyl-tag.

7. The soluble polypeptide of claim 4, wherein the polypeptide comprises an amino-tag.

8. The soluble polypeptide of claim 4, wherein the polypeptide comprises a carboxyl- and an amino-tags.

9. The soluble peptide of claim 1, wherein the peptide linker comprises a proline and a hydrophobic amino acid.

10. The soluble peptide of claim 1, wherein the peptide linker is PGGS (SEQ ID NO:

1).

11. The soluble polypeptide of claim 1, wherein the peptide linker is selected from the group consisting of:

PGGS (SEQ ID NO;

1), PGGGS (SEQ ID NO;

2), and PGGG (SEQ ID NO;

3).

12. The soluble polypeptide of claim 1, wherein the native GPCR protein is CCR5 protein comprising:

at least four domains comprising at least a portion of an N-terminal domain, an ECL1 domain, an ECL2 domain, and an ECL3 domain of CCR5, wherein each of the four domains is linked in tandem by a PGGS inter-domain linker.

13. The soluble polypeptide of claim 1, wherein the native GPCR protein is CCR5 protein comprising:

at least four domains comprising at least a portion of an N-terminal domain, an ECL1 domain, an ECL2 domain, and an ECL3 domain of CCR5, wherein each of the four domains is linked in tandem by an inter-domain linker, and at least one of the inter-domain linkers is a PGGS linker.

14. The soluble polypeptide of claim 12 or 13, further comprising one or more tags.

15. The soluble polypeptide of claim 1, wherein the native GPCR protein is CXCR4 protein comprising:

at least four domains comprising at least a portion of an N-terminal domain, an ECL1 domain, an ECL2 domain, and an ECL3 domain of CXCR4, wherein each of the four domains is linked in tandem by a PGGS inter-domain linker.

16. The soluble polypeptide of claim 1, wherein the native GPCR protein is CXCR4 protein comprising:

at least four domains comprising at least a portion of an N-terminal domain, an ECL1 domain, an ECL2 domain, and an ECL3 domain of CXCR4, wherein each of the four domains is linked in tandem by an inter-domain linker, and at least one of the inter-domain linkers is a PGGS linker.

17. The soluble polypeptide of claim 15 or 16, further comprising one or more tags.

18. The soluble polypeptide of claim 1 further comprising a CD4 N-terminal immunoglobulin variable region-like domain and a gp41 ectodomain, wherein the at least two extracellular domains of a GPCR protein, the CD4 N-terminal immunoglobulin variable region-like domain and the gp41 ectodomain are linked in tandem by short peptide linkers.

19. The soluble polypeptide of claim 1, further comprising a CD4 N-terminal immunoglobulin variable region-like domain, wherein the at least two extracellular domains of a GPCR protein and the CD4 N-terminal immunoglobulin variable region-like domain are linked in tandem by a short peptide linker.

20. The soluble polypeptide of claim 1, further comprising a gp41 ectodomain, wherein the at least two extracellular domains of a GPCR protein and the gp41 ectodomain are linked in tandem by a short peptide linker.

21. The soluble polypeptide of claim 18 or 19, wherein the CD4 N-terminal immunoglobulin variable region-like domain comprises D1 and D2 domains.

22. The soluble polypeptide of claim 18 or 20, wherein the gp41 ectodomain comprises a C-terminal intramolecular interaction domain.

23. The soluble polypeptide of claim 22, wherein the C-terminal intramolecular interaction domain is a polypeptide corresponding to amino acid residues 628-683 of gp41.

24. The soluble polypeptide of claim 18 or 20, wherein the gp41 ectodomain comprises an N-terminal intramolecular interaction domain.

25. A nucleic acid encoding the soluble polypeptide of claim 1.

26-38. -38. (canceled)

39. A method for identifying a molecule that binds to a G protein-coupled receptor (GPCR) protein of native conformation, the method comprising:

contacting a sample containing at least one test molecule with a soluble polypeptide that retains three dimensional conformation of a native GPCR protein, comprising extracellular domains of a GPCR protein, linked in tandem by short inter-domain linkers, wherein the soluble polypeptide retains three dimensional conformation of the native GPCR, and

identifying the molecule that binds to the polypeptide.

40-67. -67. (canceled)

68. A method of inhibiting ligand-dependent receptor stimulation of a G protein-coupled receptor (GPCR), the method comprising:

contacting a cell expressing the GPCR on the cell surface with a soluble polypeptide that retains three dimensional conformation of a native GPCR protein comprising;

at least two extracellular domains of a GPCR protein, linked in tandem by short inter-domain linkers to form a soluble polypeptide that retains three dimensional conformation of a native GPCR corresponding to the extracellular domains of the GPCR protein, wherein the soluble polypeptide is capable of binding a ligand or functionally equivalent analog thereof for the native GPCR protein in an amount effective for inhibiting ligand-dependent receptor stimulation of a GPCR.

69-71. -71. (canceled)

72. A method of treating an HIV infection, the method comprising:

administering to a subject in need of such treatment a composition comprising a soluble polypeptide that retains native three-dimensional conformation of extracellular portions of an HIV co-receptor, comprising at least part of an N-terminus, an ECL1 domain, an ECL2 domain and an ECL3 domain of the HIV co-receptor, linked in tandem by inter-domain PGGS linkers and disulfide bonds, in a pharmacologically effective amount to treat HIV infection.

73-81. -81. (canceled)

82. A method of treating a disease or disorder caused by a G protein-coupled receptor (GPCR) mutation, wherein the GPCR mutation is associated with altered basal activity, the method comprising:

administering to a subject in need of such treatment a composition comprising a soluble polypeptide that retains native three-dimensional conformation of extracellular portions of a GPCR, comprising at least part of an N-terminus, an ECL1 domain, an ECL2 domain and an ECL3 domain of the GPCR, linked in tandem by inter-domain linkers, wherein at least one of the inter-domain linkers comprises a PGGS linker, and disulfide bonds, in an amount effective to treat the disease or disorder caused by a GPCR mutation.

83. The method of claim 82, wherein the disease or disorder is selected from the group consisting of:

Congenital night blindness, Retinitis pigmentosa, Gastric carcinoid tumors, Kaposi'"'"'s sarcoma, primary effusion lymphoma, Atherosclerosis, infections in immunocompromised patients, Adenoma or hyperplasia associated with hyperthyroidism, Male precocious puberty, Leydig cell tumor associated with male precocious puberty, Normal semen parameters despite hypophysectomy, ansen-type metaphyseal chondrodysplasia (dwarfism, hypercalcemia, hypophosphatemia, Autosomal dominant hypocalcemia.

84-102. -102. (canceled)